Statements where consensus for inclusion in the definition is achieved or close to consensus and discussed at the consensus meeting
| Statement | N (%) voting for inclusion | N (%) of CYP voting for inclusion | Decision |
| Testing | |||
| At least one positive COVID-19 test needed | 17 (100) | 6 (75)* | Include |
| Burden of symptoms | |||
| The young person has symptoms that continue or develop after COVID-19 which impact their physical, mental or social well-being | 17 (100) | 8 (100) | Include |
| The young person has symptoms that are interfering with some aspect of daily living (eg, school, work, home, relationships) | 17 (100) | 7 (100)* | Include |
| The impact of the symptoms on functioning is at least moderate | 11 (65) | 0 (0) | Exclude |
| Persisting physical symptoms | |||
| 1 or more persisting physical symptoms | 17 (100) | 7 (88)* | Include |
| Duration | |||
| Persist for a minimum duration of 12 weeks after initial testing even if symptoms waxed and waned over that period | 17 (100) | 7 (88)* | Include |
| Persist for more than 3 months after initial testing and are from the list of common symptoms (ie, unusual tiredness, headaches, shortness of breath, loss of smell or taste, dizziness) | 0 (0) | 0 (0) | Exclude |
| Persist for more than 1 month after initial testing | 0 (0) | 0 (0) | Exclude |
| Tests to exclude other diseases | |||
| A negative glandular fever (monospot, antibody or EBV PCR) test | 0 (0) | 1 (13) | Exclude |
| A normal full blood count, CRP, ESR, urea and electrolytes, creatinine, calcium, liver function tests, random blood glucose | 0 (0) | 0 (0) | Exclude |
*One CYP was unable to vote due to technical problems.
CRP, C reactive protein; CYP, children and young people; EBV PCR, Epstein Barr virus polymerase chain reaction.